Statistics of Cell Free DNA Screening
Tracy Prosen, MD teaches you how to use statistics applied to screening and diagnostic tests in cell free DNA screenings, how to apply clinical data in real life scenarios, the role of microdeletion testing and how to avoid data that can be misleading or misperceived.
Section 1 (00:43)
Statistics of screening
a. Screening and diagnostic tests
b. Definitions of test performance
i. Screen positives and false positives
ii. Biological causes of false positives
iii. Sensitivity and specificity
iv. Screening for Down syndrome
v. Positive and negative predictive values
c. Summary and Knowledge check
Section 2 (10:45)
Clinical application: Aneuploidies
a. Considering abnormal results
i. Determining if a test is appropriate
ii. Post-test counseling
iii. Unusual circumstances
b. Knowledge check
Section 3 (19:19)
Clinical application: Microdeletions
a. Considering abnormal results
b. Knowledge check
Section 4 (22:36)
Beware of misleading data
a. Calculating PPV in a high risk population
b. Interpretation of results reported as risk figures
c. Test accuracy does not equal PPV
d. Impact of test failures on test performance
e. Impact of etiology of disease on test performance
f. Summary and Knowledge check
A global leader in DNA sequencing and array-based solutions, Illumina is dedicated to improving human health by unlocking the power of the genome. Serving customers in the research, clinical, and applied markets, Illumina technology is responsible for generating more than 90% of the world’s sequencing data. * Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, agriculture, microbiology, forensic science and beyond.
*Data calculations on file. Illumina, Inc., 2015.
Видео Statistics of Cell Free DNA Screening канала Illumina
Section 1 (00:43)
Statistics of screening
a. Screening and diagnostic tests
b. Definitions of test performance
i. Screen positives and false positives
ii. Biological causes of false positives
iii. Sensitivity and specificity
iv. Screening for Down syndrome
v. Positive and negative predictive values
c. Summary and Knowledge check
Section 2 (10:45)
Clinical application: Aneuploidies
a. Considering abnormal results
i. Determining if a test is appropriate
ii. Post-test counseling
iii. Unusual circumstances
b. Knowledge check
Section 3 (19:19)
Clinical application: Microdeletions
a. Considering abnormal results
b. Knowledge check
Section 4 (22:36)
Beware of misleading data
a. Calculating PPV in a high risk population
b. Interpretation of results reported as risk figures
c. Test accuracy does not equal PPV
d. Impact of test failures on test performance
e. Impact of etiology of disease on test performance
f. Summary and Knowledge check
A global leader in DNA sequencing and array-based solutions, Illumina is dedicated to improving human health by unlocking the power of the genome. Serving customers in the research, clinical, and applied markets, Illumina technology is responsible for generating more than 90% of the world’s sequencing data. * Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, agriculture, microbiology, forensic science and beyond.
*Data calculations on file. Illumina, Inc., 2015.
Видео Statistics of Cell Free DNA Screening канала Illumina
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Chromosomes, DNA, and Aneuploidy Syndromes | NIPT Webinar SeriesNo Rare Disease Will Go UnseenMiSeq™: How to denature and dilute libraries and spike in PhiXJoyn Ginkgo Customer StoryDevelopment and application of polygenic risk scores (PRS) - Eric BoerwinklePrenatal Screening Options: cfDNA (cell free DNA)Sensitivity & Specificity ExplainedAutomation with TruSight Oncology 500: The Customer PerspectiveSequencing: How to Plan Your First Sequencing ProjectScreening Terminology and Aneuploidy Testing Options | NIPT Webinar SeriesMiSeq™: How to start a runAdvanced prenatal genetic testingThe Key to Implementing Genomes: CollaborationHow to Clean Illumina© NGS Sequencer Wash CartridgesCan We Use Cell-Free-DNA Screening Better? By Dr. Chinmayee Ratha | LifeCell WebinarsCell-Free DNA Prenatal ScreenLibrary Prep Best Practices: Tagment Wash Buffer HandlingStatistics, Probability and Diagnostic MedicineChallenges In Interpreting Results From Pre-Implantation Genetic Testing for Aneuploidy (PGT-A)BaseSpace BCL Convert: How to Requeue Analysis for a NextSeq 1000/2000 run